A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Clinical trial NCT07638566 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07638566
- Sponsor
- argenx
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-09-01
- Primary completion
- 2028-04-01
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.